Mongolia vs Pakistan: Average cost of drugs for extensively drug-resistant tuberculosis
Mongolia
1,900 constant 2022 US$
in 2024
Pakistan
1,923 constant 2022 US$
in 2024
Mongolia rank
28th
Pakistan rank
27th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Mongolia
- Pakistan
How they compare
Pakistan currently reports 1,923 constant 2022 US$ against 1,900 constant 2022 US$ in Mongolia, a difference of 23 constant 2022 US$.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Mongolia ahead.
Mongolia ranks 28th and Pakistan ranks 27th of 56 countries.
Across the 2 decades both report, Mongolia averaged higher in 1 and Pakistan in 1.
Head to head by decade
| Decade | Mongolia | Pakistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 14,667 constant 2022 US$ | 8,635 constant 2022 US$ | 6,031 constant 2022 US$ | Mongolia |
| 2020s | 2,120 constant 2022 US$ | 2,824 constant 2022 US$ | 704 constant 2022 US$ | Pakistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Mongolia or Pakistan?
- Pakistan, at 1,923 constant 2022 US$ against 1,900 constant 2022 US$ in Mongolia as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Mongolia and Pakistan?
- 23 constant 2022 US$, with Pakistan ahead.
- How many years of comparable data are there for Mongolia and Pakistan?
- 8 years are reported by both, from 2017 to 2024.
- How do Mongolia and Pakistan rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Mongolia ranks 28th and Pakistan ranks 27th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.